Related Experiment Video
Updated: Jul 15, 2026

Flow Cytometric Analysis of Particle-bound Bet v 1 Allergen in PM10
Published on: November 19, 2016
House dust (1-3)-beta-D-glucan and wheezing in infants
Y Y Iossifova1, T Reponen, D I Bernstein
1Department of Environmental Health, University of Cincinnati, Cincinnati, OH 45267-0056, USA.
Background:
(1-3)-Beta-D-glucan is a fungal cell wall component, suspected to cause respiratory symptoms in adults. However, very little is known on the possible health effects of (1-3)-beta-D-glucan during infancy. We examined the association between (1-3)-beta-D-glucan exposure and the prevalence of allergen sensitization and wheezing during the first year of life in a birth cohort of 574 infants born to atopic parents. Endotoxin exposure was included as a possible confounder.
Methods:
(1-3)-Beta-D-glucan and endotoxin exposures were measured in settled dust collected from infants' primary activity rooms. The primary outcomes at approximately age one included parental reports of recurrent wheezing and allergen sensitization evaluated by skin prick testing to a panel of 15 aeroallergens as well as milk and egg white.
Results:
Exposure to high (1-3)-beta-D-glucan concentration (within fourth quartile) was associated with reduced likelihood of both recurrent wheezing [adjusted OR (aOR) = 0.39, 95% CI = 0.16-0.93] and recurrent wheezing combined with allergen sensitization (aOR = 0.13, 95% CI = 0.03-0.61). Similar trends were found between (1-3)-beta-D-glucan concentrations and allergen sensitization (aOR = 0.57, 95% CI = 0.30-1.10). In contrast, recurrent wheezing with or without allergen sensitization was positively associated with low (1-3)-beta-D-glucan exposure within the first quartile (aOR = 3.04, 95% CI = 1.25-7.38; aOR = 4.89, 95% CI = 1.02-23.57). There were no significant associations between endotoxin exposure and the studied health outcomes.
Conclusions:
This is the first study to report that indoor exposure to high levels of (1-3)-beta-D-glucan (concentration >60 microg/g) is associated with decreased risk for recurrent wheezing among infants born to atopic parents. This effect was more pronounced in the subgroup of allergen-sensitized infants.
Insights
High indoor exposure to (1-3)-beta-D-glucan may protect infants from wheezing and allergen sensitization. This fungal component showed a reduced risk for recurrent wheezing, especially in allergen-sensitized infants.
Area of Science:
- Environmental health
- Pediatric allergy
- Mycology
Background:
- Fungal (1-3)-beta-D-glucan is linked to adult respiratory issues.
- Limited data exists on infant exposure and health effects.
- This study investigates (1-3)-beta-D-glucan's impact on infant wheezing and sensitization.
Purpose of the Study:
- To determine the association between indoor (1-3)-beta-D-glucan exposure and infant wheezing.
- To assess the link between (1-3)-beta-D-glucan exposure and allergen sensitization in infants.
- To explore the role of endotoxin as a potential confounder.
Main Methods:
- A birth cohort of 574 infants born to atopic parents was studied.
- (1-3)-Beta-D-glucan and endotoxin levels were measured in settled dust.
- Outcomes included parental reports of wheezing and skin prick testing for sensitization at age one.
Main Results:
- High (1-3)-beta-D-glucan exposure was associated with reduced wheezing (aOR=0.39) and combined wheezing/sensitization (aOR=0.13).
- A trend towards reduced sensitization was observed with higher (1-3)-beta-D-glucan levels (aOR=0.57).
- Low (1-3)-beta-D-glucan exposure correlated with increased wheezing risk.
Conclusions:
- High indoor (1-3)-beta-D-glucan levels (>60 microg/g) may decrease recurrent wheezing risk in infants from atopic families.
- This protective effect is more significant in allergen-sensitized infants.
- No significant associations were found between endotoxin exposure and the studied health outcomes.
More Related Videos
06:34A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
Published on: June 4, 2017
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
Related Concept Videos
Asthma I: Introduction
Asthma-I: Introduction
Asthma III: Clinical Manifestations
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Allergic Reactions
Asthma-III: Symptoms and Complications
Classification of Asthma